Sperotto F, Gutiérrez-Sacristán A, Makwana S, Li X, Rofeberg VN, Cai T, Bourgeois FT, Omenn GS, Hanauer DA, Sáez C, Bonzel CL, Bucholz E, Dionne A, Elias MD, García-Barrio N, González TG, Issitt RW, Kernan KF, Laird-Gion J, Maidlow SE, Mandl KD, Ahooyi TM, Moraleda C, Morris M, Moshal KL, Pedrera-Jiménez M, Shah MA, South AM, Spiridou A, Taylor DM, Verdy G, Visweswaran S, Wang X, Xia Z, Zachariasse JM, Aaron JR, Adam A, Agapito G, Albayrak A, Albi G, Alessiani M, Alloni A, Amendola DF, Angoulvant F, Anthony LL, Aronow BJ, Ashraf F, Atz A, Avillach P, Panickan VA, Azevedo PS, Badenes R, Balshi J, Batugo A, Beaulieu-Jones BR, Beaulieu-Jones BK, Bell DS, Bellasi A, Bellazzi R, Benoit V, Beraghi M, Bernal-Sobrino JL, Bernaux M, Bey R, Bhatnagar S, Blanco-Martínez A, Boeker M, Booth J, Bosari S, Bradford RL, Brat GA, Bréant S, Brown NW, Bruno R, Bryant WA, Bucalo M, Burgun A, Cannataro M, Carmona A, Cattelan AM, Caucheteux C, Champ J, Chen J, Chen KY, Chiovato L, Chiudinelli L, Cho K, Cimino JJ, Colicchio TK, Cormont S, Cossin S, Craig JB, Cruz-Bermúdez JL, Cruz-Rojo J, Dagliati A, Daniar M, Daniel C, Das P, Devkota B, Duan R, Dubiel J, DuVall SL, Esteve L, Estiri H, Fan S, Follett RW, Ganslandt T, Garmire LX, Gehlenborg N, Getzen EJ, Geva A, Goh RS, Gradinger T, Gramfort A, Griffier R, Griffon N, Grisel O, Guzzi PH, Han L, Haverkamp C, Hazard DY, He B, Henderson DW, Hilka M, Ho YL, Holmes JH, Honerlaw JP, Hong C, Huling KM, Hutch MR, Jannot AS, Jouhet V, Kainth MK, Kate KF, Kavuluru R, Keller MS, Kennedy CJ, Key DA, Kirchoff K, Klann JG, Kohane IS, Krantz ID, Kraska D, Krishnamurthy AK, L'Yi S, Leblanc J, Lemaitre G, Lenert L, Leprovost D, Liu M, Will Loh NH, Long Q, Lozano-Zahonero S, Luo Y, Lynch KE, Mahmood S, Makoudjou A, Malovini A, Mao C, Maram A, Maripuri M, Martel P, Martins MR, Marwaha JS, Masino AJ, Mazzitelli M, Mazzotti DR, Mensch A, Milano M, Minicucci MF, Moal B, Moore JH, Morris JS, Mousavi S, Mowery DL, Murad DA, Murphy SN, Naughton TP, Breda Neto CT, Neuraz A, Newburger J, Ngiam KY, Njoroge WF, Norman JB, Obeid J, Okoshi MP, Olson KL, Orlova N, Ostasiewski BD, Palmer NP, Paris N, Patel LP, Pfaff AC, Pfaff ER, Pillion D, Pizzimenti S, Priya T, Prokosch HU, Prudente RA, Prunotto A, Quirós-González V, Ramoni RB, Raskin M, Rieg S, Roig-Domínguez G, Rojo P, Romero-Garcia N, Rubio-Mayo P, Sacchi P, Salamanca E, Samayamuthu MJ, Sanchez-Pinto LN, Sandrin A, Santhanam N, Santos JC, Sanz Vidorreta FJ, Savino M, Schriver ER, Schubert P, Schuettler J, Scudeller L, Sebire NJ, Serrano-Balazote P, Serre P, Serret-Larmande A, Hossein Abad ZS, Silvio D, Sliz P, Son J, Sonday C, Strasser ZH, Tan AL, Tan BW, Tan BW, Tanni SE, Terriza-Torres AI, Tibollo V, Tippmann P, Toh EM, Torti C, Trecarichi EM, Vallejos AK, Varoquaux G, Vella ME, Vie JJ, Vitacca M, Wagholikar KB, Waitman LR, Wassermann D, Weber GM, Wolkewitz M, Wong S, Xiong X, Ye Y, Yehya N, Yuan W, Zahner JJ, Zambelli A, Zhang HG, Zöller D, Zuccaro V, Zucco C (2023)
Publication Type: Journal article
Publication year: 2023
Book Volume: 64
DOI: 10.1016/j.eclinm.2023.102212
BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras. METHODS: We performed a multicentre observational retrospective study including seven paediatric hospitals in four countries (France, Spain, U.K., and U.S.). All consecutive confirmed patients with MIS-C hospitalised between February 1st, 2020, and May 31st, 2022, were included. Electronic Health Records (EHR) data were used to calculate pooled risk differences (RD) and effect sizes (ES) at site level, using Alpha as reference. Meta-analysis was used to pool data across sites. FINDINGS: Of 598 patients with MIS-C (61% male, 39% female; mean age 9.7 years [SD 4.5]), 383 (64%) were admitted in the Alpha era, 111 (19%) in the Delta era, and 104 (17%) in the Omicron era. Compared with patients admitted in the Alpha era, those admitted in the Delta era were younger (ES -1.18 years [95% CI -2.05, -0.32]), had fewer respiratory symptoms (RD -0.15 [95% CI -0.33, -0.04]), less frequent non-cardiogenic shock or systemic inflammatory response syndrome (SIRS) (RD -0.35 [95% CI -0.64, -0.07]), lower lymphocyte count (ES -0.16 × 109/uL [95% CI -0.30, -0.01]), lower C-reactive protein (ES -28.5 mg/L [95% CI -46.3, -10.7]), and lower troponin (ES -0.14 ng/mL [95% CI -0.26, -0.03]). Patients admitted in the Omicron versus Alpha eras were younger (ES -1.6 years [95% CI -2.5, -0.8]), had less frequent SIRS (RD -0.18 [95% CI -0.30, -0.05]), lower lymphocyte count (ES -0.39 × 109/uL [95% CI -0.52, -0.25]), lower troponin (ES -0.16 ng/mL [95% CI -0.30, -0.01]) and less frequently received anticoagulation therapy (RD -0.19 [95% CI -0.37, -0.04]). Length of hospitalization was shorter in the Delta versus Alpha eras (-1.3 days [95% CI -2.3, -0.4]). INTERPRETATION: Our study suggested that MIS-C clinical phenotypes varied across SARS-CoV-2 eras, with patients in Delta and Omicron eras being younger and less sick. EHR data can be effectively leveraged to identify rare complications of pandemic diseases and their variation over time. FUNDING: None.
APA:
Sperotto, F., Gutiérrez-Sacristán, A., Makwana, S., Li, X., Rofeberg, V.N., Cai, T.,... Zucco, C. (2023). Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium. EClinicalMedicine, 64. https://doi.org/10.1016/j.eclinm.2023.102212
MLA:
Sperotto, Francesca, et al. "Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium." EClinicalMedicine 64 (2023).
BibTeX: Download